Pyrazoles

Publication Title: 
Spine

STUDY DESIGN: A randomized controlled clinical trial was conducted. OBJECTIVE: To compare medication, needle acupuncture, and spinal manipulation for managing chronic (>13 weeks duration) spinal pain because the value of medicinal and popular forms of alternative care for chronic spinal pain syndromes is uncertain. SUMMARY OF BACKGROUND DATA: Between February 1999 and October 2001, 115 patients without contraindication for the three treatment regimens were enrolled at the public hospital's multidisciplinary spinal pain unit.

Author(s): 
Giles, Lynton G. F.
Muller, Reinhold
Publication Title: 
Spine

STUDY DESIGN: A randomized controlled clinical trial was conducted. OBJECTIVE: To compare medication, needle acupuncture, and spinal manipulation for managing chronic (>13 weeks duration) spinal pain because the value of medicinal and popular forms of alternative care for chronic spinal pain syndromes is uncertain. SUMMARY OF BACKGROUND DATA: Between February 1999 and October 2001, 115 patients without contraindication for the three treatment regimens were enrolled at the public hospital's multidisciplinary spinal pain unit.

Author(s): 
Giles, Lynton G. F.
Muller, Reinhold
Publication Title: 
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica

In a previous paper, we reported that PZ-177 had potent anti-inflammatory and analgesic activities. In the present work, acute toxicity and action of PZ-177 on the central nervous system were tested in comparison with PZ-222, one of metabolites of PZ-177, and mepirizole. Acute toxicity of PZ-177 was slightly less than that of aminopyrine and the same as that of mepirizole in mice and rats. PZ-177 produced from sedation to loss of righting reflex with the increase of dose.

Author(s): 
Tsurumi, K.
Go, K.
Fujimura, H.
Publication Title: 
The Journal of Pharmacy and Pharmacology

The liver alcohol dehydrogenase inhibitor, 4-methylpyrazole, has been tested for its ability to change the hypnotic concentrations of phenobarbitone (phenobarbital) in rats. Following a single dose of 1 mmol kg-1 i.v., administered 60 min before phenobarbitone, 4-methylpyrazole shortened the onset time and reduced the dose of phenobarbitone required to produce loss of righting reflex. Consistent with this, phenobarbitone concentrations in serum (both total and free), brain and in cerebrospinal fluid at onset of hypnosis were about half in 4-methylpyrazole compared with saline-treated rats.

Author(s): 
Ramzan, I.
Publication Title: 
Oncotarget

CUSP9 treatment protocol for recurrent glioblastoma was published one year ago. We now present a slight modification, designated CUSP9*. CUSP9* drugs--aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, sertraline, ritonavir, are all widely approved by regulatory authorities, marketed for non-cancer indications. Each drug inhibits one or more important growth-enhancing pathways used by glioblastoma. By blocking survival paths, the aim is to render temozolomide, the current standard cytotoxic drug used in primary glioblastoma treatment, more effective.

Author(s): 
Kast, Richard E.
Karpel-Massler, Georg
Halatsch, Marc-Eric
Publication Title: 
Biochemical and Biophysical Research Communications
Author(s): 
Tu, Y. Y.
Sonnenberg, J.
Lewis, K. F.
Yang, C. S.
Publication Title: 
Archives of Biochemistry and Biophysics

Metabolism of nitrosamines was studied in a reconstituted monooxygenase system composed of cytochrome P-450 isozymes purified from liver microsomes of ethanol- and phenobarbital-treated rats. The ethanol-induced isozyme (P-450et) was efficient in catalyzing the demethylation of N-nitrosodimethylamine (NDMA), with a Km of 2.4 mM and Vmax of 7.2 nmol min-1 nmol P-450(-1), but less active with N-nitrosomethylbenzylamine and N-nitrosomethylaniline.

Author(s): 
Tu, Y. Y.
Yang, C. S.
Publication Title: 
Rheumatology (Oxford, England)

OBJECTIVE: To demonstrate clinical equivalence between two standardized Ayurveda (India) formulations (SGCG and SGC), glucosamine and celecoxib (NSAID). METHODS: Ayurvedic formulations (extracts of Tinospora cordifolia, Zingiber officinale, Emblica officinalis, Boswellia serrata), glucosamine sulphate (2 g daily) and celecoxib (200 mg daily) were evaluated in a randomized, double-blind, parallel-efficacy, four-arm, multicentre equivalence drug trial of 24 weeks duration. A total of 440 eligible patients suffering from symptomatic knee OA were enrolled and monitored as per protocol.

Author(s): 
Chopra, Arvind
Saluja, Manjit
Tillu, Girish
Sarmukkaddam, Sanjeev
Venugopalan, Anuradha
Narsimulu, Gumdal
Handa, Rohini
Sumantran, Venil
Raut, Ashwinikumar
Bichile, Lata
Joshi, Kalpana
Patwardhan, Bhushan
Publication Title: 
In Vivo (Athens, Greece)

Celecoxib (C), a COX-2 enzyme inhibitor, was administered at a 0.1% dose level in the diet of female Swiss Webster CFW outbred mice for life. The mice also received 1,2-dimethylhydrazine dihydrochloride (1,2-DMH) as 10 weekly subcutaneous injections at 20 microg/g body weight. The number of animals with large intestinal cancer and the total number of these cancers were 30 and 321 in the 1,2-DMH-treated group, while the corresponding figures in the C and 1,2-DMH-treated group were 29 and 156. This difference is statistically highly significant.

Author(s): 
Coles, Melissa
Toth, Bela
Publication Title: 
In Vivo (Athens, Greece)

In this serial sacrifice experiment, celecoxib (C) was administered at a 0.1% dose level, in the diet of female Swiss Webster CFW outbred mice. The animals also received either 1,2-dimethylhydrazine dihydrochloride (1,2-DMH) as ten weekly subcutaneous (s.c.) injections at 20 microg/g body weight or physiological saline (PS) as ten weekly s.c. injections at 0.01 ml/g body weight. Subsequently, the mice were sacrificed at 26 weeks or 35 weeks after the first injection of 1,2-DMH or PS.

Author(s): 
Toth, Bela
Coles, Melissa

Pages

Subscribe to RSS - Pyrazoles